QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dow-dips-over-200-points-rpm-international-shares-fall-after-q3-results

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow...

 why-staar-surgical-shares-are-trading-higher-by-around-13-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...

 nasdaq-surges-1-conagra-brands-posts-upbeat-earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow ...

 cancer-focused-effector-therapeutics-shelves-development-of-lung-cancer-candidate-after-disappointing-data

eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib sh...

 dow-jumps-over-100-points-us-jobless-claims-increase-to-221000

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the marke...

 effector-therapeutics-announces-topline-results-of-phase-2-kickstart-trial-of-tomivosertib-combined-with-pembrolizumab-in-non-small-cell-lung-cancer

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) fo...

 hc-wainwright--co-reiterates-buy-on-effector-therapeutics-maintains-24-price-target

HC Wainwright & Co. analyst Robert Burns reiterates eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy and maintains $24 pri...

 effector-therapeutics-cash-cash-equivalents-and-short-term-investments-totaling-184m-as-of-december-31-2023-anticipates-that-it-will-be-sufficient-to-fund-operations-into-q1-of-2025

Fourth Quarter and Full Year 2023 Financial ResultsCash Position and Guidance: The company had cash, cash equivalents, and shor...

 effector-therapeutics-q4-eps-342-misses-165-estimate

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(3.42) per share which missed the analyst consensus estimate ...

 hc-wainwright--co-maintains-buy-on-effector-therapeutics-adjusts-price-target-to-24

HC Wainwright & Co. analyst Robert Burns maintains eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy, adjusts target to $24...

 effector-therapeutics-announces-15m-registered-direct-offering-priced-at-the-market-under-nasdaq-rules

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) (the "Company"), a leader in the development of selective translation regulat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION